Thank you, Bob. And good morning, everyone. As Bob said, I remain incredibly enthusiastic about the accomplishments of Team Summit and our partnership with Akeso. Before providing on some of the highlights, as Bob mentioned, I would like to discuss the clinical work that has been conducted with ivonescimab. There are more than 25 clinical trials around the globe evaluating ivonescimab across 17 tumor settings, including nine Phase 3 trials planned, ongoing or completed either in China or globally. While six of the Phase 3 programs across Summit and Akeso are currently focused in non-small cell lung cancer, three additional Phase 3 clinical trials have been announced by Akeso evaluating our lead candidate in solid tumor settings beyond non-small cell lung cancer. This include BTC, head and neck cancer and pancreatic cancer. At Summit, we are sponsoring two ongoing Phase 3 clinical trials, HARMONi and HARMONi-3. We are planning to initiate HARMONi-7 in early 2025. Based on the data Bob mentioned that was released at ESMO that I will speak more to it in a moment, we are excited to and are actively exploring expanding our Summit led clinical development plan beyond metastatic non-small cell lung cancer. As a reminder, ivonescimab is the only PD-1 VEGF bispecific antibody in Phase 3 in our licensed territories. Ivonescimab brings these two highly validated mechanism of action together into one novel molecule targeting simultaneously both PD-1 and VEGF. Next, I would like to review the many achievements completed as well as discuss some upcoming catalysts for the remainder of this year. The third quarter of 2024 was a landmark moment for ivonescimab and its development with significant catalyst events in the form of data related in September at the World Lung and ESMO conferences. Last month at the World Lung Conference, HARMONi-2 results were featured as part of the Presidential Symposium and received a tremendous response from leading KOLs. In this head to head trial comparing ivonescimab versus pembro, both as monotherapy, HARMONi-2 met its primary endpoint of progression free survival with ivonescimab achieving a 49% reduction in the risk of disease progression or death compared to pembro. Ivonescimab showed consistent clinically meaningful benefit across key subgroups, including patients with either PD-L1 low or PD-L1 high expressing tumors and in squamous and nonsquamous histologies. Consistent with previous studies, ivonescimab demonstrated an acceptable and manageable safety profile. With the additional Phase 2 data released in the third quarter at both World Lung and ESMO, we continue to expand the meaningful data that has been generated with ivonescimab in various solid tumor settings beyond non-small cell lung cancer. We are fortunate to have created such a strong partnership in our ongoing collaboration with Akeso as we leverage data from multiple solid tumor studies, supporting and informing Summit's own late stage clinical development strategy in our licensed territories. In addition to touching on our current clinical development plans, we initiated our strategic alliances with the University of Texas MD Anderson Cancer Center this quarter, providing additional opportunities to evaluate ivonescimab in tumor types and settings in which we have not yet tested its potential. Patients are expected to soon begin treatment and clinical development effort will soon begin via this collaboration. After the HARMONi-2 data was announced, we have received inbound interest from physicians regarding approximately 75 proposed investigator sponsored trials or ISTs in a wide range of cancer types. With meaningful updates this past quarter from Akeso’s HARMONi-2 study and several Phase 2 studies, we wanted to take the opportunity to review the respective study designs and further highlight key results. We will start with HARMONi-2. HARMONi-2 is a randomized, double blind clinical trial, evaluating frontline monotherapy, ivonescimab, as compared to monotherapy, pembro, in patients with locally advanced or metastatic non-small cell lung cancer with positive PD-L1 expression. This is a single region multicenter Phase 3 clinical trial conducted and sponsored by Akeso in China. Our partners at Akeso generated and analyzed the data in HARMONi-2. Here is the primary endpoint of progression free survival by blinded independent radiologic review committee for the entire study at the time of the first planned interim analysis, with a median follow-up of 8.67 months demonstrating a significant improvement for ivonescimab with a hazard ratio of 0.51 corresponding to a 49% improvement over the control arm. The median PFS was 11.1 months versus 5.8 months in the ivonescimab and pembro arms respectively. Of note, the curves begin to separate at the first point of radiographic assessment and maintain separation over the entire duration of follow-up thus far. The analysis of PFS subgroups reveals that the PFS benefit with ivonescimab was observed across nearly all subgroups. Specifically, the benefit is quite comparable across the spectrum of PD-L1 expression with a hazard ratio of 0.54 for patients with PD-L1 low expressing tumors and 0.46 for patients with tumors of high PD-L1 expression. As previously discussed, and this is particularly true in the United States and Europe, monotherapy checkpoint inhibitor usage is a standard of care for patients with high PD-L1 expression. With regard to non-small cell lung cancer histology, the benefit was also similar for patients with squamous non-small cell lung cancer who showed a hazard ratio of 0.48 favoring ivonescimab and those patients with tumors of non-squamous histology with a hazard ratio of 0.54 favoring ivonescimab. This slide is a strong indicator that the benefit was seen across clinical subgroups and underscores that the success of the trial overall was not driven by an especially strong performance of a subgroup. For safety, we see that there was a numerically higher rate of serious treatment related adverse events with ivonescimab 20.8% compared to 16.1%. This did not translate to greater treatment discontinuation or treatment related adverse events leading to death, both of which were numerically higher in the pembro arm. This pattern held true in patients with squamous non-small cell lung cancer as well, a place where anti-VEGF therapy has historically demonstrated safety risk where there were comparable rates of serious treatment related adverse events, discontinuation and death in the ivonescimab arm compared with the pembro arm. This is the first randomized Phase 3 clinical trial evaluating the safety profile of ivonescimab in the squamous population, especially confirming its tolerability in this group. In more detail, we see that nearly all of the higher rate of treatment related adverse events were lab related abnormalities, hypertension and proteinuria but generally did not lead to discontinuation of dosing. These are conditions that are often seen by oncologists who in general are experienced managing these [AEs]. Finally, looking at the immune related and possibly VEGF related adverse events, in the table to the left, we see comparable immune related AEs with ivonescimab compared to pembro. On the right, we see that, as expected, ivonescimab was associated with more possibly VEGF related AEs, both in all grades and grade 3 or higher. Importantly, however, all grade 3 or higher AEs were all classified as grade 3. There were no grade 4 or grade 5 AEs that were possibly VEGF related in either arm of the study. The table in the bottom line shows that most of the possible VEGF related adverse events represented proteinuria and hypertension. There is no evidence of life threatening or fatal bleeding complications, including among patients with advanced squamous non-small cell lung cancer and in patients with central tumors, cavitory lesions and/or tumor encasing large blood vessels in this Phase 3 study. As a result of the successful HARMONi-2 study and our analysis of the underlying data, we announced our plan to initiate HARMONi-7, a randomized global Phase 3 study evaluating ivonescimab versus pembro, both monotherapy in frontline non-small cell lung cancer in their PD-L1 high expression population. HARMONi-7 is planned with the two primary endpoints, progression free survival and overall survival. We are planning for an estimated 780 patients in this registration enabling study. Turning to HARMONi-3. As Bob mentioned, we intend to amend this randomized global Phase 3 clinical trial to include patients with tumors of non-squamous histology in addition to continuing to enroll squamous patients. As part of the trial amendment, the primary endpoint is intended to be updated to include two primary endpoints of progression free survival and overall survival. The total sample size for this randomized multi-regional Phase 3 clinical trial has been adjusted to include an estimated 1,080 patients. Expanding HARMONi-3 is the most efficient way to cover all metastatic non-small cell lung cancer patients without [driver] mutation. HARMONi-3 will now cover metastatic non-small cell lung cancer, both squamous and non-squamous tumors in combination with chemotherapy and HARMONi-7 intend to cover PD-L1 high expressing tumors via monotherapy ivonescimab now providing the opportunity to capture a significantly broadened addressable market as quickly as possible. Supporting this proposed amendment, in part, is both the result of HARMONi-2 showing benefit to patients with both squamous and non-squamous tumors as well as the Phase 2 data that has been previously presented. As a reminder, updated Phase 2 data for this setting was announced at the 2024 European Lung Cancer Conference in March from the AK112-201 clinical trial centered around the cohort of patients in which ivonescimab is combined with chemotherapy for first line treatment of squamous and non-squamous advanced or metastatic non-small cell lung cancer in patients without actionable genomic alterations. This data was generated and analyzed by Akeso. First line patients with advanced or metastatic non-squamous tumors experienced a median progression free survival of 13.3 months. In addition, first line advanced or metastatic squamous patients experienced median progression free survival of 11.1 months. Both metrics are encouraging considering the expectation for the current standard of care in this patient population largely driven by PD-1 inhibitors plus chemotherapy. Median overall survival was not reached in either subset of patients after a median follow-up time of approximately 22.1 months. The frequency of treatment emergent adverse events leading to the discontinuation of ivonescimab was 11.1% and 2.8% respectively in patients with squamous and non-squamous tumor. We are highly encouraged by the opportunity of ivonescimab to demonstrate its potential across non-small cell lung cancer in multiple clinical settings. Finally, as we have stated, we are evaluating opportunity to expand our clinical development beyond metastatic non-small cell lung cancer. We will review the encouraging Phase 2 data announced this past quarter at World Lung and ESMO, starting with an overview of the respective study design. At the World Lung, perioperative non-small cell lung cancer Phase 2 data was featured from AK112-205, a single region, multi-center, open-label study of patients with Stage II or III resectable non-small cell lung cancer with data generated analyzed by Akeso. The study was designed to assess patients receiving either ivonescimab monotherapy or ivonescimab plus chemotherapy prior to surgical resection and then ivonescimab monotherapy after surgery. Due to the maturity of the data and the timing of the data cut-off, the results were mature for the neo adjuvant portion of the clinical trial. In September 2024, promising antitumor activity and safety data for ivonescimab were presented at ESMO. Featuring updated data in advanced triple negative breast cancer, recurrent metastatic head and neck squamous cell cancer carcinoma and metastatic microsatellite stable colorectal cancer. The head and neck study assessed patients who received ivonescimab with or without ligufalimab with PD-L1 positive locally advanced or metastatic recurrent head and neck squamous cell carcinoma. Note that ligufalimab, or AK117, is Akeso’s proprietary investigational product that is not approved by any regulatory authority and to which Summit does not have any license or ownership rights. The colorectal study was designed to assess patients who were randomly assigned to receive ivonescimab plus FOLFOXIRI with or without ligufalimab, an investigational anti CD47 monoclonal antibody. The triple negative breast cancer study assessed patients who received ivonescimab plus chemotherapy, either paclitaxel or nab-paclitaxel with locally advanced or metastatic TNBC. Turning now to anti-tumor activity and safety data from this Phase 2 study. In perioperative non-small cell lung cancer at the time of data cut-off, 49 patients had been enrolled into the ivonescimab plus chemotherapy arm in the neo adjuvant setting. Of these 49 patients, 39 went on to complete surgery. Of the 39 patients who received ivonescimab plus chemotherapy in the neo adjuvant stage and completed surgery, 71.8% of patients experienced a major pathological response and 43.6% of patients experienced a pathological complete response. In the 49 patients enrolled in this cohort, median event free survival was not yet reached after 8.9 months of the median follow-up time. The 12 months event free survival rate was 80.3%. These results are encouraging compared to the historical data that has been observed in global pivotal studies in a similar setting. The safety profile in this Phase 2 study was acceptable and manageable. No surgeries were delayed or canceled due to the treatment related adverse events. In colorectal cancer, at the time of data cut off, 22 patients received ivonescimab plus FOLFOXIRI with a median follow-up time of nine months. 18 patients received ivonescimab plus ligufalimab plus FOLFOXIRI with a median follow-up time of 9.6 months. All patients in both groups experienced a reduction in their tumor burden compared to their baseline tumor assessment. The overall response rate and DCR for the 39 patients combined from both groups who had at least one post baseline tumor assessment was 84.6% and 100% respectively. Median progression free survival was not reached in either group at the time of this analysis. The safety profile in this Phase 2 study was acceptable and manageable. These response rate are very encouraging considering historical benchmarks in this setting. In addition, these patients have tumors that are considered microsatellite stable, a setting where PD-1 therapy has not been historically successful. This is another indicator of ivonescimab potential beyond the current PD-1 landscape. In triple negative breast cancer, at the time of data cut off, 30 patients received ivonescimab plus chemotherapy with median follow-up time of 10.2 months, 60% of patients had previously received taxane based chemotherapy in either the neo adjuvant or adjuvant settings in this Phase 2 data set. All patients experienced a reduction in their tumor burden compared to their baseline tumor assessment. The overall response rate and DCR for the 29 patients who had at least one post baseline tumor assessment were 72.4% and 100% respectively. Median progression free survival was 9.3 months at the time of this analysis. The safety profile in this Phase 2 study was acceptable and manageable. The PD-L1 low or negative TNBC is yet another clinical setting without PD-1 therapy as a standard of care. Moving to head and neck, at the time of data cut off, 10 patients received ivonescimab with median follow-up of 3.3 months and 20 patients received ivonescimab plus ligufalimab with median follow-up 4.1 months. All patients had tumors with PD-L1 expression. The overall response rate and DCR for the 30 patients combined was 50% and 86.7%, respectively. The safety profile in this Phase 2 study was acceptable and manageable. The third quarter of 2024 was a pivotal moment in cementing the growing confidence of ivonescimab. Before I turn it over to Manmeet to provide a financial update, I would like to take a moment to thank our incredible team at Summit. As Bob and I have described all of the accomplishments we have achieved over the past seven quarters with ivonescimab, this team has done a remarkable job across every team in making our goals a reality and condensing time where and when possible to accelerate our timeline in bringing additional therapeutic options to patients with cancer. It is a tremendous honor and privilege to work with each member of Team Summit, and I would like to express my heartfelt thanks to everyone of our phenomenal team member. With that update, I will now ask Manmeet to provide details on our financial position and operational update.
